Arcus Biosciences Inc at Evercore ISI HealthCONx Conference Transcript
Hey, guys, thank you all for joining us. A pleasure to have the entire management team from Arcus join us today. We have a ton to talk about. But before we do, let me first turn over to Terry. Terry, what's on top of your mind, your top priorities as we head into the new year?
Sure. Thanks, Umer. I'll spend a few minutes just telling you how we're looking at things. So 2020 was obviously a year of a lot of execution, our collaboration with Gilead, collaboration with AstraZeneca. If you look across our programs, whether it's AB928; AB680 in the adenosine space; or AB154, our anti-TIGIT antibody, largely, you could look at this year as having been one that was focused on dose-escalation studies, dose-expansion studies and the early start of randomized studies.
So we've been pushing, since the founding of the company in 2015, to really get to what 2021 will offer,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |